Baseline (Prevention)

This class includes 3-MeO-PCP, PCEs, fluorinated/chlorinated ketamine analogs, and synthetic cannabinoids. These compounds interact with NMDA, sigma, CB1, 5-HT2A, and dopamine systems in complex ways.

• Prevent rapid tolerance by limiting use to once every 3–4 weeks

• Never mix two compounds from this class

• Avoid combining with SSRIs or MAOIs due to unpredictable interactions

Active Tachyphylaxis

If tolerance develops:

• Stop all use for a minimum of 3–4 weeks

• Receptor desensitization is often non-linear

• Use magnesium and zinc daily

• For cannabinoid-specific tachyphylaxis:

  • Introduce CB1 antagonists like rimonabant (if accessible)

  • Consider fatty acid amide hydrolase inhibitors (e.g., CBD)

• Avoid high-THC cannabis during this window

Withdrawal Transition

• Buffer neurochemical rebound with:

  • Taurine

  • L-theanine

  • Agmatine (modulates NMDA and opioid tone)

  • Low-dose clonidine if necessary

• Support cannabinoid recovery with:

  • Omega-3s

  • Choline precursors

• Ensure glutamate stability via magnesium threonate and NAC

Neurorestoration Phase

• Rebuild receptor sensitivity and neuroarchitecture with:

  • 7,8-DHF

  • Lion’s mane

  • Citicoline

  • Uridine

  • Aerobic training

• For synthetic cannabinoid recovery, add:

  • Low-dose CBD

  • Pregnenolone

  • PPAR agonists (e.g., oleoylethanolamide)

• Reinforce recovery with sleep, fasting, and cold exposure

Maintenance / Reinforcement

• Use only as rare tools for self-exploration

• Never stack or co-administer with depressants or disinhibitors

• Restore euphoria via natural methods:

  • Oxytocin release

  • Music

  • Emotional intimacy

• Preserve cognitive integrity with weekly cholinergic and dopaminergic maintenance